UK markets close in 4 hours 4 minutes

Oryzon Genomics S.A. (0RDB.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.6800-0.0250 (-0.92%)
As of 11:55AM GMT. Market open.

Oryzon Genomics S.A.

Sant Ferran 74
Cornellà de Llobregat 08940
Spain
34 93 515 13 13
http://www.oryzon.com

Sector(s)
Industry
Full-time employees40

Key executives

NameTitlePayExercisedYear born
Dr. Carlos Manuel Buesa ArjolCo-Founder, Chairman, CEO & Pres58kN/AN/A
Mr. Enric RelloCOO & CFON/AN/AN/A
Dr. Torsten HoffmannChief Scientific OfficerN/AN/A1967
Mr. Emili TorrellChief Bus. Devel. OfficerN/AN/AN/A
Ms. Neus VirgiliChief Intellectual Property OfficerN/AN/AN/A
Dr. Cesar MolineroChief Clinical OfficerN/AN/AN/A
Dr. Roger BullockChief Medical OfficerN/AN/AN/A
Ms. Sonia GutierrezChief of Clinical OperationsN/AN/AN/A
Mr. Augusto Pinel RubioSec.N/AN/AN/A
Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Corporate governance

Oryzon Genomics S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.